BioSpace News Archive

In medical settings, power cut-offs are not merely an inconvenience but can be a life-or-death issue.

A study published in the Journal of Clinical Psychopharmacology found that an FDA cleared, computer-based, objective measurement of attention-deficit/hyperactivity disorder (ADHD) symptoms was more sensitive to medication effects than patient self-rating, at both one-month and six-month follow-up visits

After the post-vaccination death of a 56-year-old Florida physician from a brain hemorrhage, and reports of clotting problems worldwide after the Astra-Zeneca jab, Lee Merritt, M.D., undertook a review of reports in the Vaccine Adverse Event Reporting System of reactions to Pfizer and Moderna products that possibly were related to platelet problems.

DiFusion Technologies, maker of the ZFUZE™ suite of surgical polymers, today announced the addition of Todd Potokar to its Board of Directors.

EvoEndo® Inc., (“EvoEndo” or “the Company”) a preclinical medical device company developing systems for unsedated Transnasal Endoscopy (TNE), announced it has secured $10.1M in equity financing.

LARVOL, the leading provider of data and intelligence solutions for oncologists and the pharmaceutical and biotech industries, today announced the launch of CLIN, an easy-to-navigate platform that curates ten years of historical clinical trial data, with an initial focus on immuno-oncology.

Kaiser Permanente, the nation’s largest integrated, nonprofit health care provider, is joining the White House for its National Month of Action sprint to vaccinate 70% of adults in the U.S. against COVID-19 with at least one shot by July 4.

The conference will be held virtually on July 13 and 14. Greg McKee, Chairman and CEO; Jim Gilligan, President and Chief Science Officer; and Luke Hayes, CFO, will provide an overview of Tryp’s business and its pipeline followed by a brief analyst-led fireside chat.

Company Invites Individual and Institutional Investors, as well as Advisors and Analysts, to Attend the Company’s Virtual Presentation on Thursday, June 10, 2021.

The market for colorectal cancer drugs is driven by frequent diagnostic tests and drug launches.